- Vedolizumab for perianal fistulizing Crohn’s disease: systematic review and meta-analysis
-
Ayoub F, Odenwald M, Micic D, Dalal SR, Pekow J, Cohen RD, Rubin DT, Sakuraba A
- KMID: 2529570
- Intest Res.
- 2022 Apr;20(2):240-250.
- doi: 10.5217/ir.2021.00091
Background/Aims: Perianal fistulas are a debilitating manifestation of Crohn’s disease (CD). Despite the advent of anti-tumor necrosis factor (anti-TNF) therapy, the medical management of fistulizing CD continues to be challenged... -
- CITED
-
- Close
- SHARE
-
- Close
- Factors associated with anti-tumor necrosis factor effectiveness to prevent postoperative recurrence in Crohn’s disease
-
Buisson A, Cannon L, Umanskiy K, Hurst RD, Hyman NH, Sakuraba A, Pekow J, Dalal S, Cohen RD, Pereira B, Rubin DT
- KMID: 2531984
- Intest Res.
- 2022 Jul;20(3):303-312.
- doi: 10.5217/ir.2021.00018
Background/Aims: We assessed the effectiveness of anti-TNF agents and its associated factors to prevent endoscopic and clinical postoperative recurrence (POR) in Crohn’s disease (CD). Methods: From a prospectively-maintained database, we... -
- CITED
-
- Close
- SHARE
-
- Close
